News & Updates

Show Multimedia Only

Ultrathin bronchoscopy boasts higher diagnostic yield for peripheral pulmonary lesions

Ultrathin bronchoscopy boasts higher diagnostic yield for peripheral pulmonary lesions

The diagnostic yield for peripheral pulmonary lesions is higher with ultrathin bronchoscopy compared to thin bronchoscopy, as shown in a study, noting that a radial probe endobronchial ultrasound (rEBUS) cannot be inserted through a thin bronchoscope.

Is first-line lazertinib monotherapy a potential new SoC for EGFRm NSCLC?

Is first-line lazertinib monotherapy a potential new SoC for EGFRm NSCLC?

Patients with EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) exhibited significantly improved progression-free survival (PFS) when treated with lazertinib compared with gefitinib in the first-line setting, results of the LASER301 trial showed.

10 Feb 2023

Reduced lung function may induce hypertension

Reduced lung function may induce hypertension

Reduced lung function may induce hypertension

Reduced lung function, regardless of smoking status, contributes to an increased hypertension prevalence, reports a study.

10 Feb 2023

Ultrathin bronchoscopic cryobiopsy safe, effective for lesions probe

Ultrathin bronchoscopic cryobiopsy safe, effective for lesions probe

The feasibility of ultrathin bronchoscopic cryobiopsy has been proven recently in a study, which also demonstrates its effectiveness and safety for the diagnosis of peripheral pulmonary lesions.

Anti-MDA5 antibody–positive dermatomyositis with anti-Ro52 ups ILD, mortality risks

Anti-MDA5 antibody–positive dermatomyositis with anti-Ro52 ups ILD, mortality risks

Patients with dermatomyositis (DM) who are positive for antimelanoma differentiation-associated gene 5 antibody (anti-MDA5) are more likely to have anti-Ro52 antibodies as well, and such coexistence appears to heighten the risks of rapidly progressive interstitial lung disease (ILD) and mortality, suggests a recent study.

Hormone therapies up ILD events in men with prostate cancer

Hormone therapies up ILD events in men with prostate cancer

Hormone therapy drugs, such as bicalutamide, flutamide, nilutamide, goserelin, degarelix, and apalutamide, appear to increase the likelihood of developing interstitial lung disease (ILD) events in patients with prostate cancer, reports a study.

04 Feb 2023

Does molnupiravir improve outcomes in vaccinated COVID-19 patients?

Does molnupiravir improve outcomes in vaccinated COVID-19 patients?

The addition of molnupiravir to usual care does not reduce hospitalization or death in vaccinated, community-dwelling individuals at high risk of serious outcomes of COVID-19, results of the UK-based PANORAMIC trial showed. However, it may provide other benefits such as reducing time to recovery.

03 Feb 2023

$Is hypofractionated better than conventionally fractionated RT for stage I NSCLC?$

Is hypofractionated better than conventionally fractionated RT for stage I NSCLC?

Hypofractionated radiotherapy (HFRT) is not superior to conventionally fractionated radiotherapy (CFRT) in providing survival benefits to patients with stage I nonsmall cell lung cancer (NSCLC), but HFRT is preferable due to its convenience and lower costs, according to a study.

03 Feb 2023

COVID-19 vaccines partially effective against Omicron BA.2 infection in children and adolescents in HK

COVID-19 vaccines partially effective against Omicron BA.2 infection in children and adolescents in HK

According to a retrospective, territory-wide, case-based study, the mRNA-based BNT162b2 vaccine and inactivated CZ02 vaccine were partially effective against SARS-CoV-2 infection in children and adolescents during the Omicron BA.2 wave in Hong Kong.

02 Feb 2023

Study supports safety of fourth BNT162b2 mRNA vaccine

Study supports safety of fourth BNT162b2 mRNA vaccine

A study from Israel validated the safety of the fourth BNT162b2 mRNA COVID-19 vaccine (ie, second booster) using data from a retrospective and a prospective cohort.

01 Feb 2023

Something went wrong.